Literature DB >> 32386313

Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis.

Palna Mehta1, Ronald G Nahass2,3, Luigi Brunetti1,4.   

Abstract

BACKGROUND: Studies have had conflicting results regarding the influence of acid-suppression medications (ASMs) during hospitalization on the recurrence of Clostridioides difficile infection (CDI).
METHODS: A systematic review and meta-analysis investigating the association between recurrent CDI and ASM use in inpatients was performed. Relevant literature was identified using Medline, Google Scholar, and Web of Science. All human studies were considered regardless of publication date. Case-control and cohort studies and clinical trials were included if they contained the necessary information to calculate appropriate statistics related to the objective of this study. Review articles, meta-analyses, and commentaries were excluded; however, their references were searched to identify any studies missed. The random-effects model was selected since significant heterogeneity in study design was identified. To evaluate the sensitivity of the analysis various subgroup analyses were performed.
RESULTS: Our search identified 9 studies involving 5668 patients of whom 1003 (17.7%) developed recurrent CDI. Patients on ASM were 64% more likely to develop recurrent CDI than patients not on ASM (OR, 1.64; 95% CI, 1.13-2.38; P = .009; I2 = 79.54%). Proton pump inhibitor (PPI) use was associated with an 84% increased risk of recurrent CDI versus no ASM (OR, 1.84; 95% CI, 1.18-2.85; P = .007; I2 = 83.4%).
CONCLUSIONS: ASM use during hospitalization was associated with a 64% increase in recurrent CDI. The association was greater with PPI use. Due to significant heterogeneity in the analyses, additional studies are essential to further elucidate iatrogenic effects of ASM. Unnecessary PPI use should be discontinued.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Clostridioides difficile infection; acid suppression; histamine 2 receptor antagonists; meta-analysis; proton pump inhibitors

Year:  2021        PMID: 32386313      PMCID: PMC8246810          DOI: 10.1093/cid/ciaa545

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  21 in total

1.  Overuse of acid-suppressive therapy in hospitalized patients.

Authors:  R J Nardino; R J Vender; P N Herbert
Journal:  Am J Gastroenterol       Date:  2000-11       Impact factor: 10.864

Review 2.  Recurrent Clostridium difficile diarrhoea.

Authors:  L Kyne; C P Kelly
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

3.  Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis.

Authors:  Abhishek Deshpande; Chaitanya Pant; Vinay Pasupuleti; David D K Rolston; Anil Jain; Narayan Deshpande; Priyaleela Thota; Thomas J Sferra; Adrian V Hernandez
Journal:  Clin Gastroenterol Hepatol       Date:  2011-10-20       Impact factor: 11.382

4.  Risk factors for severity and relapse of pseudomembranous colitis in an elderly population.

Authors:  M Moshkowitz; E Ben-Baruch; Z Kline; Z Shimoni; M Niven; F Konikoff
Journal:  Colorectal Dis       Date:  2007-02       Impact factor: 3.788

Review 5.  Clostridium difficile infection: new insights into management.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Mayo Clin Proc       Date:  2012-11       Impact factor: 7.616

Review 6.  Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.

Authors:  Raseen Tariq; Siddharth Singh; Arjun Gupta; Darrell S Pardi; Sahil Khanna
Journal:  JAMA Intern Med       Date:  2017-06-01       Impact factor: 21.873

7.  Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain.

Authors:  Dolors Rodríguez-Pardo; Benito Almirante; Rosa M Bartolomé; Virginia Pomar; Beatriz Mirelis; Ferran Navarro; Alex Soriano; Luisa Sorlí; Joaquín Martínez-Montauti; Maria Teresa Molins; Maily Lung; Jordi Vila; Albert Pahissa
Journal:  J Clin Microbiol       Date:  2013-02-27       Impact factor: 5.948

8.  Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease.

Authors:  M N Choudhry; H Soran; H M Ziglam
Journal:  QJM       Date:  2008-04-14

9.  Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.

Authors:  Daniel E Freedberg; Hojjat Salmasian; Carol Friedman; Julian A Abrams
Journal:  Am J Gastroenterol       Date:  2013-09-24       Impact factor: 10.864

10.  Proton pump inhibitors alter the composition of the gut microbiota.

Authors:  Matthew A Jackson; Julia K Goodrich; Maria-Emanuela Maxan; Daniel E Freedberg; Julian A Abrams; Angela C Poole; Jessica L Sutter; Daphne Welter; Ruth E Ley; Jordana T Bell; Tim D Spector; Claire J Steves
Journal:  Gut       Date:  2015-12-30       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.